Edgewise Therapeutics announced the appointment of R. Michael Carruthers to the newly created position of Chief Financial Officer (CFO). Mr. Carruthers brings over two decades of experience serving as CFO for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including initial public offerings, capital raising strategy and mergers and acquisitions. This comes at an important time as Edgewise advances EDG-5506, the company’s lead product candidate, in clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD). Prior to joining Edgewise, Mr. Carruthers served as fractional CFO for several private and public companies.